Press "Enter" to skip to content

Remdesivir did not cut hospital stay or mortality in COVID patients: WHO

Gilead Sciences Inc’s remdesivir had little or no effect on COVID-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found. The antiviral medication was among the first to be used as a treatment for COVID-19. It was also used recently to treat US President Donald Trump, who was suffering from COVID-19. The results are from WHO’s “Solidarity” trial, which evaluated the effects of four potential drug regimens, including remdesivir, hydroxychloroquine, anti-HIV drug combination and interferon, in 11,266 adult patients across more than 30 countries.

Leave your comments

%d bloggers like this: